What is the recommended dosing regimen for a single 5 mg vial of a GLP‑1 receptor agonist intended for one month of therapy in an adult with type 2 diabetes or obesity and no known hypersensitivity?

GLP-1 Receptor Agonist Dosing: 5 mg Monthly Vial Guidance

For a single 5 mg vial intended for one month of therapy, you are describing tirzepatide (Mounjaro/Zepbound), which is dosed at 5 mg subcutaneously once weekly—meaning one 5 mg vial provides approximately one month (4 weeks) of treatment. This is the FDA-approved starting maintenance dose after initial titration. 1

Dosing Protocol for Tirzepatide 5 mg Weekly

Initial Month (Weeks 1–4)

• Administer 5 mg subcutaneously once weekly on the same day each week, injecting into the abdomen, thigh, or upper arm. 1
• This 5 mg dose serves as the initial maintenance dose after completing the 2.5 mg weekly lead-in period (if treatment-naïve), or as the direct starting dose when switching from another GLP-1 receptor agonist. 1, 2
• One 5 mg vial = four weekly injections = one month of therapy. 1

Expected Outcomes at 5 mg Weekly

• Weight loss: Approximately 5.5 kg (12 pounds) reduction over the first 4–12 weeks, with mean weight loss reaching 12.8% by week 72 in clinical trials. 1, 2
• Glycemic control: HbA1c reduction of approximately 1.9–2.1% from baseline in patients with type 2 diabetes. 1
• Gastrointestinal tolerance: Nausea occurs in 17–22% of patients, diarrhea in 13–16%, and vomiting in 6–10%, with symptoms typically mild-to-moderate and resolving within 4–8 weeks. 1

Concomitant Medication Adjustments

Insulin Management

• Reduce basal insulin by 20% when starting tirzepatide to prevent hypoglycemia (e.g., if on 12 units daily, reduce to 10 units). 1
• For patients with HbA1c <8%, consider a more aggressive 30% reduction. 1

Sulfonylurea Management

• Discontinue sulfonylureas entirely or reduce dose by 50% before initiating tirzepatide to avoid additive hypoglycemia risk. 1

DPP-4 Inhibitor Management

• Stop all DPP-4 inhibitors (sitagliptin, linagliptin, etc.) before starting tirzepatide—concurrent use provides no additional benefit. 1

Monitoring Schedule

Week 4 Assessment

• Evaluate gastrointestinal tolerance (nausea, vomiting, diarrhea) before considering dose escalation. 1
• Check fasting glucose and assess for hypoglycemia, especially if on insulin or sulfonylureas. 1
• Monitor blood pressure, as weight loss may necessitate antihypertensive medication adjustments. 1

Week 12–16 Assessment

• Re-measure HbA1c to determine glycemic response and decide whether to escalate to 10 mg weekly. 1
• Assess weight loss progress—if <5% weight loss after 3 months, consider discontinuation or alternative therapy. 1
• Evaluate for signs of pancreatitis (persistent severe abdominal pain) or gallbladder disease (right-upper-quadrant pain with fever). 1

Absolute Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)—these are absolute contraindications based on animal studies showing thyroid C-cell tumors. 1
• Severe hypersensitivity reaction to tirzepatide. 1

Dose Escalation After First Month

• After ≥4 weeks on 5 mg weekly, if glycemic targets are not met or additional weight loss is needed, escalate to 10 mg weekly for another ≥4 weeks. 1
• After ≥4 weeks on 10 mg weekly, consider escalation to the maximum approved dose of 15 mg weekly if further intensification is required. 1
• Never escalate more frequently than every 4 weeks—rapid titration is the primary cause of intolerable gastrointestinal side effects and treatment discontinuation. 1

Special Populations

Renal Impairment

• No dose adjustment required for any level of renal impairment, including eGFR <30 mL/min/1.73 m² and end-stage renal disease. 1
• Monitor closely for dehydration if severe gastrointestinal side effects occur, as this increases acute kidney injury risk. 1

Hepatic Impairment

• No dose adjustment required for hepatic impairment. 1

Common Pitfalls to Avoid

• Do not skip the 5 mg starting dose when initiating therapy—this is essential to minimize gastrointestinal side effects that can cause treatment discontinuation in 8–10% of patients. 1
• Do not escalate doses more rapidly than every 4 weeks—this dramatically raises the risk of severe nausea, vomiting, and diarrhea. 1
• Do not combine tirzepatide with other GLP-1 receptor agonists—this offers no additional benefit and increases adverse event burden. 1
• Do not restart at a higher dose after missing ≥3 consecutive weekly injections—restart the full titration schedule from 2.5 mg or 5 mg to avoid severe gastrointestinal toxicity. 1

Missed Dose Management

• If ≤4 days since missed dose: Administer as soon as possible and resume regular weekly schedule. 1
• If >4 days since missed dose: Skip the missed dose and resume at next scheduled dose. 1
• If ≥3 consecutive doses missed: Consider restarting the titration schedule from 2.5 mg or 5 mg weekly. 1